Rajendra Singh, PhD

Assessment of the deutetrabenazine exposure-response relationships for patients with moderate-to-severe tardive dyskinesia

Abstract: Background: Deutetrabenazine (Teva) is indicated for chorea associated with Huntington’s disease and tardive dyskinesia (TD). Individual optimization of treatment based on effi...

Rajendra Singh , PhD;

01/19/2023

Exposure–Response Analysis to Compare Changes in the Clinical Endpoints for Tardive Dyskinesia and Chorea in Huntington Disease Following Once-Daily and Twice-Daily Tablet Formulations of Deutetrabenazine

Exposure-Response models using predicted exposure of deutetrabenazine’s active metabolites following BID and QD formulation administration, and therapeutic responses in the phase 3 TD and...

Rajendra Singh , PhD;

10/26/2023